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Objectives: The objective of this study was to improve the prediction of the impact of HIV-1 protease mutations in
different viral subtypes on virological response to darunavir.
Methods: Darunavir-containing treatment change episodes (TCEs) in patients previously failing PIs were selected
from large European databases. HIV-1 subtype B-infected patients were used as the derivation dataset and HIV-
1 non-B-infected patients were used as the validation dataset. The adjusted association of each mutation with
week 8 HIV RNA change from baseline was analysed by linear regression. A prediction model was derived based
on best subset least squares estimation with mutational weights corresponding to regression coefficients.
Virological outcome prediction accuracy was compared with that from existing genotypic resistance interpret-
ation systems (GISs) (ANRS 2013, Rega 9.1.0 and HIVdb 7.0).
Results: TCEs were selected from 681 subtype B-infected and 199 non-B-infected adults. Accompanying drugs
were NRTIs in 87%, NNRTIs in 27% and raltegravir or maraviroc or enfuvirtide in 53%. The prediction model included
weighted protease mutations, HIV RNA, CD4 and activity of accompanying drugs. The model’s association with
week 8 HIV RNA change in the subtype B (derivation) set was R2¼0.47 [average squared error (ASE)¼0.67,
P,1026]; in the non-B (validation) set, ASE was 0.91. Accuracy investigated by means of area under the receiver
operating characteristic curves with a binary response (above the threshold value of HIV RNA reduction) showed
that our final model outperformed models with existing interpretation systems in both training and validation sets.
Conclusions: A model with a new darunavir-weighted mutation score outperformed existing GISs in both B and
non-B subtypes in predicting virological response to darunavir.
# The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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Introduction
HIV-1 drug resistance is a major limitation to the efficacy of com-
bination ART (cART).1,2 With several available drug options, the
aim of cART is to achieve full virological suppression even in
treatment-experienced patients with multi-class drug resist-
ance.3 – 5 Darunavir is a PI requiring pharmacokinetic boosting
with ritonavir, with preserved antiviral activity against several
PI-resistant HIV-1 isolates,6 – 9 and has a documented activity
against non-B HIV-1 subtypes.10 The tight binding between daru-
navir and the active viral protease site and its ability to inhibit
protease dimerization form the basis for this preserved activity
and high genetic barrier to resistance.6 – 15
The higher efficacy of darunavir/ritonavir as compared with
other PIs has been demonstrated in highly treatment-experienced
patients with extensive drug resistance.12 Nonetheless, in the pres-
ence of a high number of resistance mutations in the viral protease,
combination regimens with darunavir/ritonavir will ultimately fail.
It is therefore important to identify the combinations of protease
substitutions that result in a loss of darunavir activity. Several
scores and algorithms for the interpretation of darunavir genotypic
resistance [genotypic resistance interpretation systems (GISs)]
have been constructed.16 – 25 However, different GISs vary with
respect to the mutations that are taken into account and the
weights assigned to the individual mutations. This variation may
be explained by the inclusion of different source studies and the
use of different analytical approaches. Moreover, although most
knowledge on darunavir resistance is based on subtype B viruses,
other subtypes are becoming increasingly relevant due to the
extension of cART coverage in African and Asian countries where
non-B subtypes prevail, and to the spread of non-B viruses in
Europe and North America.26 – 28 Therefore, the precise impact of
HIV-1 protease mutations and their combinations on virological
response to darunavir remains to be fully elucidated, particularly
with different subtypes.
We aimed to derive a refined genotypic interpretation score for
darunavir based on virological response in patients harbouring
subtype B HIV-1, and to validate its performance for non-B
HIV-1 subtypes.
Methods
Case selection and definition of treatment change
episodes (TCEs)
We selected darunavir-containing TCEs from European observational
cohort studies sharing their data through the CHAIN project,29 namely
EuResist (gathering data from Italy, Germany, Sweden, Belgium and
Portugal),30 the Swiss HIV cohort study,31 the Aquitaine cohort32 and
cohorts from Paris and Rome, and through the Treatment Change
Episodes Database of COHERE in EuroCoord, a collaboration of European
cohorts (www.cohere.org). COHERE’s Treatment Change Episodes
Database was pooled within the EuroCoord network in 2012 (www.
EuroCoord.net).
Cases were required to be HIV-infected adults (≥18 years old). A TCE
was defined as the start of a darunavir-containing regimen including at
least two additional antiretroviral agents in patients with a previous his-
tory of virological failure to at least one PI (HIV RNA .1000 copies/mL
after at least 3 months of treatment). Not all participating cohorts were
able to provide information on darunavir dose; for those that did, only
cases receiving 600 mg twice daily were included. Cases were required
to have an available drug resistance genotype (protease and reverse tran-
scriptase sequences obtained through standard population sequencing)
and an HIV-1 RNA quantification and CD4 count performed within the per-
iod from 6 months before to 1 week after baseline (the start date of the
darunavir regimen). Additional variables necessary for inclusion were
prior treatment history and drugs accompanying darunavir and HIV-1
RNA at week 8 (window+4 weeks) after baseline; gender and age were
not required for inclusion but were collected. No regimen change was
allowed between the date of sample collection for pre-baseline viral
load and resistance genotyping and the baseline, and the darunavir-
containing regimen had to be prescribed for at least 12 weeks without
changes or interruptions. All cases gave written informed consent within
the respective cohorts. Viral subtype was determined using the Rega
2.0 subtyping system. Unassigned subtypes were classified as non-B.
Statistical analysis
Definition of main outcome variable
The main outcome was change in log10 HIV RNA from baseline to week
8. An undetectable viral load at week 8 was imputed with a value of
50 copies/mL (main analysis) or 25 copies/mL (sensitivity analysis).
Definition of PI mutations
Any protease substitution at any codon (compared with consensus B
reference sequence) with a frequency.2% was considered as a candidate
PI mutation.
Prediction model derivation strategy
We used a standard linear regression model applied to the derivation data-
set to identify predictive mutations from the candidate protease muta-
tions. Regression models included candidate protease mutations,
adjusting for the following variables: baseline log10 viral load; baseline
CD4 cell count; and genotypic susceptibility score (GSS) of drugs prescribed
with darunavir. The GSS of the drugs accompanying darunavir was calcu-
lated by summing the number of active drugs using the interpretation of
the ANRS 2013 algorithm (HIVdb 7.0 with three resistance categories21
was used in sensitivity analyses); individual drug activity was scored as 1
if there was no evidence of resistance, 0.5 if there was intermediate resist-
ance and 0 if there was resistance. New and recycled use of raltegravir,
enfuvirtide and maraviroc was scored 1 and 0, respectively.
The derivation set comprised all TCE cases with subtype B virus and the
validation dataset comprised all non-B subtype cases.
Least squares estimation (LSE) was used to select the ‘best’ subset of
mutations. The LSE chosen to minimize the average squared error (ASE)
was based on a 5-fold cross-validation (CV). Briefly, 5-fold CV works by div-
iding the derivation dataset randomly into five equal parts. The method
fits the model to four-fifths of the data and then computes the prediction
error on the remaining one-fifth. This procedure was applied to each fifth
of the dataset and the five prediction error estimates were averaged. From
this procedure we obtained an estimated prediction of the 5-fold CV error
(CV PRESS) curve, which was used to establish a threshold for stopping the
inclusion of the covariates. In sensitivity analyses, we also investigated
the effect of allowing for 2-way interactions between mutation terms
and the use of 10-fold CV. CV was applied to the derivation dataset to
select the best model providing the final set of mutations defining the
score. The final prediction model included the individual selected muta-
tions, along with baseline CD4 and HIV RNA and GSS of the accompanying
drugs, which were forced into the model.
Validation of the score model
The performance of the final model was evaluated in different ways. First,
the ASEs on both derivation and validation sets were compared. For
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completeness the R2 on the derivation set was also shown. Second, we
computed prediction accuracy of the final model and compared it with
a model including only the adjustment variables (the ‘base model’ with
baseline log10 viral load, baseline CD4 cell count and GSS of the accom-
panying drugs) and with models including adjustment variables and the
darunavir level of resistance from three main existing GISs (ANRS 2013,
Rega 9.1.0 and HIVdb 7.0) using area under the receiver operating charac-
teristic (AUROC) curves. This was applied to both the derivation and the
validation set. For each existing GIS a dummy variable indicating resist-
ance was created: for ANRS and Rega ‘no resistance’ and ‘intermediate
resistance’ were considered as ‘no resistance’; for HIVdb, ‘susceptible’,
‘potential low-level resistance’ and ‘low-level resistance’ were considered
as ‘no resistance’. This required also the transformation of the viral
load reduction at week 8 into a binary outcome (response) using three levels
of HIV-1 RNA reduction from baseline (.1, .1.5 and .2 log10 copies/mL).
Statistical analyses were performed using procedures GLMSELECT and
LOGISTIC in SAS 9.3 (SAS Institute, Cary, NC, USA, 2013).
Results
Baseline patient characteristics
Eight hundred and eighty cases fulfilled the selection criteria: 681
(77.4%) were infected with a subtype B virus (derivation dataset)
and 199 (22.6%) were infected with a non-B virus (validation set).
Non-B subtypes consisted mainly of subtype A (19.6%), CRF02_AG
(18.6%), C (14.1%), D (7%), F (6.5%), unique recombinant forms
(5.5%), G (4.5%), BF recombinants (2.5%), others (12.5%) and
unassigned (9%). The main baseline characteristics of study
patients overall and in the derivation and validation datasets
are summarized in Table 1. The numbers contributed by each
cohort are illustrated in Table S1 (available as Supplementary
data at JAC Online). The patients were heavily pretreated, with
previous experience of a median of five different NRTIs and
three different PIs, including tipranavir in one-quarter. The major-
ity had also experienced NNRTIs and almost one-half other drug
classes. Patients infected with non-B viruses differed from those
infected with subtype B viruses, with a higher proportion of
females, a lower median HIV-1 RNA, slightly lower CD4 counts
and a smaller number of previously experienced antiretro-
viral drugs.
The distribution of protease substitutions from consensus B
virus by viral subtype category is illustrated in Figure 1. Among
the mutations included in the IAS-USA list of major and minor dar-
unavir resistance mutations16 (Figure 1a), V32I, L33F, I47V and
I84V were more frequent in the subtype B subset as compared
with the non-B, while L89V was more frequent in non-B subtypes.
For the other mutations (Figure 1b and c) there were differences in
frequency at several polymorphic positions, while among substi-
tutions associated with resistance to PIs there was a higher fre-
quency for L10I, M46I/L, A71V, G73S, V77I, V82A and L90M in
subtype B, whereas K20I, M36I, K70R, T74S, L89I/M prevailed
among the non-B subtypes. Figure 1(d) illustrates the proportion
of cases with full resistance to at least one drug in each class and
the proportion with resistance to at least one drug to all three his-
torical classes, in subtype B and non-B subtype TCEs, according to
HIVdb interpretation. Subtype B cases had a higher proportion
with resistance to NRTIs and PIs and a higher proportion of three-
class resistance compared with non-B subtypes.
Antiretroviral drugs accompanying darunavir
The antiretrovirals used in combination with darunavir/ritonavir
and their GSS are summarized in Table 2. About one in four
patients used NNRTIs and around one-half were prescribed an
integrase inhibitor or entry inhibitor. The single drugs more fre-
quently used in combination with darunavir/ritonavir were tenofo-
vir, raltegravir, enfuvirtide and etravirine, most of these reflecting
the treatments employed in heavily experienced patients with
multi-class resistant viruses. Individuals with non-B viruses were
treated less frequently with raltegravir, enfuvirtide and etravirine,
while showing a slightly higher GSS for the accompanying drugs.
Association of protease mutations with 8 week viral
load changes in the derivation set (subtype B) and
model derivation
In the derivation dataset, median week 8 HIV-1 RNA change
from baseline was 22.01 (IQR 22.68, 21.03) log10 copies/mL,
with 41.4% achieving ,50 copies/mL at this timepoint. In the
Table 1. Patient characteristics at baseline
All (n¼880) Subtype B (n¼681) Non-B subtypes (n¼199)
Age (years), median (IQR) 42.7 (41.6–44.6) 42.6 (41.5–44.6) 43.4 (42.1–44.7)
Male, n (%) 688 (78.2) 583 (85.6) 105 (52.8)
HIV RNA (log10 copies/mL), median (IQR) 4.3 (3.3–4.9) 4.4 (3.5–4.9) 3.9 (3.1–4.8)
CD4 count (cells/mm3), median (IQR) 215 (96–363) 220 (98–370) 197 (90–330)
Number of previously used antiretroviral drugs, median (IQR) 9 (4–13) 10 (4–13) 7 (3–11)
Number of previously used NRTIs, median (IQR) 5 (2–6) 5 (3–6) 4 (2–6)
Number of previously used NNRTIs, median (IQR) 1 (0–2) 1 (0–2) 1 (0–1)
Number of previously used PIs, median (IQR) 3 (1–5) 3 (1–5) 2 (1–4)
Previous lopinavir use, % 70.1 70.2 69.8
Previous tipranavir use, % 25.3 26.7 20.6
Previous etravirine use, % 8.8 9.1 7.5
Previous enfuvirtide use, % 27.3 29.4 20.1
Previous raltegravir use, % 10.0 10.0 10.1
Previous maraviroc use, % 8.1 7.9 8.5
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validation set the week 8 HIV-1 RNA change was21.57 (IQR22.43,
20.52) log10 copies/mL, with 41.1% achieving ,50 copies/mL.
Five mutations (L10F, V11L, I54M, T74P and V82I) were associated
with reduced response while six substitutions (K20T, E34D, I64L,
V82A, I85V and I93L) correlated with improved response
(Table 3). The final model included the selected protease muta-
tions, baseline CD4, HIV RNA and GSS for the accompanying
drugs. The parameters of the model are reported, with the regres-
sion coefficient of each individual component indicating its
predicted contribution to the 8 week change from baseline HIV
RNA (in log10 copies/mL): intercept +1.499; baseline HIV RNA
(per 1 log higher) 20.728; baseline CD4 count (per 100 cells/mm3
higher) 20.048; GSS (by ANRS 2013, per 1 point higher) 20.083;
L10F +0.319; V11L +0.405; I54M +0.747; T74P +0.401; V82I
+0.537; K20T 20.335; E34D 20.752; I64L 20.471; V82A
20.194; I85V 20.276; I93L 20.161. For each individual case,
the predicted 8 week HIV RNA change (in log10 copies/mL) is the
result of the algebraic sum of the products of the individual com-
ponents value times the respective regression coefficient.
Derived model performance and comparison with
available GISs
The correlation between the 8 week viral load changes predicted
by the derived score and those observed in the derivation set is
illustrated in Figure 2. Performance of the final regression model
and the different models from sensitivity analyses is summarized
in Table 4. As expected, the derived score performed better
in training than in validation sets. In the training set, our final
model performed much better than the model without any resist-
ance variables (base model) and better than models with existing
GISs. There was no such difference in the validation set. In
Table 2. Antiretrovirals accompanying darunavir/ritonavir
All
(n¼880)
Subtype
B (n¼681)
Non-B
subtypes
(n¼199)
Any NRTI (%) 87.2 86.9 87.9
Any NNRTI (%) 27.5 28.3 24.6
Any raltegravir, enfuvirtide or
maraviroc (%)
52.8 54.6 46.7
Tenofovir (%) 62.5 62.3 63.3
Nevirapine (%) 1.8 1.5 3.0
Efavirenz (%) 3.0 3.2 2.0
Etravirine (%) 23.1 24.1 19.6
Enfuvirtide (%) 24.2 25.6 19.6
Enfuvirtide first-time use (%) 13.4 13.7 12.6
Raltegravir (%) 28.8 29.2 27.1
Raltegravir first-time use (%) 24.2 24.8 23.1
Maraviroc (%) 5.9 5.9 6.0
Maraviroc first-time use (%) 4.5 5.0 3.0
GSS of the accompanying drugs
0–1 41.3 43.4 34.2
.1–2 41.3 39.4 48.2
.2 17.3 17.3 17.6
0
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Figure 1. Resistance mutations and interpretations in baseline genotypes
of TCEs with subtype B virus (derivation set) and non-B subtypes
(validation set): proportion (%) of genotypes with IAS-USA 2014
darunavir mutations (a), proportions with any protease mutation from
consensus B with a frequency of .2% (b and c) and proportion with full
resistance (R) to at least one drug in each class and to the three
historical classes, based on HIVdb 9.0 interpretation (d).
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sensitivity analyses, the performance of these different models
was broadly similar, except when undetectable viral load was
fixed at 25 copies/mL, and most of the mutations kept in the
final set were similar.
Table 5 summarizes the accuracy of the prediction of viral load
‘response’ at 8 weeks (using a threshold of 1.5 log10 copies/mL
HIV-1 RNA reduction) for the model with the newly derived daru-
navir score and three existing GISs (see Table S2 for results with
threshold values of 1 and 2 log10 copies/mL) using AUROC curves.
Among the 681 patients infected with a subtype B virus,
444 (65%) had a .1.5 log10 copies/mL reduction (response) at
8 weeks and 101 (51%) among the 199 patients infected with a
non-B virus. Two sets of comparisons were performed. First, we
compared the accuracy of the response prediction by the different
models including darunavir genotypic resistance interpretation
(‘final model’ in Tables 4, 5 and S2 and three available GIS models)
with the base model, which incorporated only CD4, HIV-1 RNA and
GSS of the accompanying drugs. Of note, all darunavir resistance
interpretation systems showed a better prediction than the base
model, demonstrating the added value of the different darunavir
resistance interpretations. Second, we compared the existing dar-
unavir GISs with the final model. In the derivation set, the new
score of the final model consistently out-performed the existing
GISs in terms of accuracy, regardless of the definition of viral
load response.
In the validation set, consisting of non-B subtypes, the greater
accuracy of the new score was evident in several analyses.
Indeed, the final model was the only model showing consistently
higher AUROC values as compared with the base model in predict-
ing the 8 week virological response, using all viral load reduction
thresholds (Tables 5 and S2). Moreover, the final model showed
higher AUROC values as compared with the models of the existing
darunavir GIS, with significant differences over ANRS and HIVdb
at the 1.5 log copies/mL threshold (Table 5), over ANRS at the
1.0 log copies/mL and over all three GISs at the 2.0 log copies/
mL threshold (Table S2).
Table 3. Linear regression model of the association of protease mutations
with 8 week viral load changes; subtype B is the derivation set (n¼681)
Protease
substitution
from
consensus B
Frequency
(%)
Adjusted mean
difference in viral load
change at week 8
(log10 copies/mL)
a SEMa P
L10F 14.5 +0.32 0.09 0.0006
V11L 2.6 +0.40 0.20 0.045
I54M 6.1 +0.75 0.14 ,0.0001
T74P 6.9 +0.40 0.13 0.0022
V82I 2.5 +0.54 0.21 0.011
K20T 4.9 20.34 0.15 0.026
E34D 2.1 20.75 0.23 0.001
I64L 2.5 20.47 0.21 0.029
V82A 29.2 20.19 0.07 0.007
I85V 6.6 20.28 0.13 0.036
I93L 39.5 20.16 0.07 0.017
aResults represent mean+SEM of 5-fold CV. Positive values indicate less
virological response (resistance) and negative values indicate better
virological response (hypersusceptibility). Associations are adjusted for
baseline HIV RNA and CD4 and GSS of the companion drugs.
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Figure 2. Eight-week HIV RNA changes from baseline: predicted versus
observed outcomes in the derivation set (subtype B TCEs). R2¼0.47.
Table 4. ASE and R2 for the final model and models investigated in
sensitivity analyses on the derivation and validation sets
Derivation set
Validation set ASEModel ASE R2
Final modela 0.67 0.47 0.91
Base modelb 0.76 0.40 0.92
ANRS 2013c 0.72 0.44 0.94
HIVdb 7.0c 0.73 0.43 0.95
Rega 9.1.0c 0.74 0.42 0.91
Sensitivity analyses on the derived model
10-foldd 0.67 0.47 0.91
25 copies/mL 0.77 0.41 1.04
2-way interactionse 0.68 0.48 0.91
GSS HIVdbf 0.68 0.46 0.93
aLSE using the model including the derived weighted darunavir mutations,
baseline CD4 and HIV-1 RNA and GSS of the accompanying drugs
(according to ANRS 2013 interpretation).
bLSE using the final model without the derived weighted darunavir muta-
tions (i.e. using only baseline CD4 and HIV-1 RNA and GSS of the accom-
panying drugs).
cLSE models including the available darunavir genotypic interpretations,
baseline CD4, HIV-1 RNA and GSS of the accompanying drugs.
d10-fold CV was used instead of 5-fold; 25 copies/mL, undetectable value
replaced with 25 copies/mL.
eSignificant 2-way interactions between mutations terms retained in the
final model.
fThe final model is adjusted for the GSS of the drugs accompanying daru-
navir computed according to HIVdb 7.0 instead of ANRS 2013.
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Discussion
Darunavir with ritonavir is one of the most widely used drugs in
patients with virological failure, and is an essential component
of salvage therapy for those who have previously failed other PI
therapies.33 Accurate information on the predicted activity of dar-
unavir based on the results of resistance genotyping enables deci-
sions on whether it should be prescribed in the new regimen, as
well as the requirement for active companion drugs. Several pre-
vious studies have focused on the interpretation of darunavir
resistance.17 – 20,24,34,35 However, analyses were either based on
genotypic analysis of clinical trials, which used specific selection
criteria, or were performed using observational data with a limited
size24 or without external validation. Moreover, the performance
of predictions was mostly based on sets of cases infected with
subtype B virus, yet non-B variants predominate in resource-
limited settings and are spreading in Europe. Given the poly-
morphic variability in the viral protease across different subtypes,
it is essential to test how darunavir resistance interpretation per-
forms in non-B subtypes.
In this study, we used the largest dataset of darunavir-based
TCEs from PI-experienced HIV-1-infected patients collected to
date. This allowed us to use two independent sets of data: one
consisted of subtype B TCEs, to derive a new weighted score,
and a separate second set consisted of non-B subtype TCEs, for
validation.
The main finding of this study was that a model including the
new weighted score was more accurate in predicting the viro-
logical response at 8 weeks compared with three popular existing
GISs for darunavir. While this was expected for B subtypes, due to
training on the same dataset, the model including the new daru-
navir score also outperformed GIS prediction of virological out-
come in an independent validation set of non-B subtypes.
Previously existing GISs were consistently less accurate in pre-
dicting virological response in non-B subtypes. In particular, none
of the existing GISs significantly improved prediction of response
to darunavir over a prediction made on the basis of CD4, viral load
and GSS of the accompanying drugs (the base model). This
indicates that renewed efforts are necessary to improve the
understanding of protease resistance interpretation in non-B sub-
types. Notably, the weighted darunavir resistance score devel-
oped in the present study and included in the final prediction
model resulted in an improved prediction of 8 week viral load out-
come in non-B subtypes compared with both the base model and
other existing GISs, using different virological response thresholds,
indicating that the weighted mutation score included in the mod-
els is of relevance in this context.
The derived score includes five protease mutations that were
associated, with different weights, with reduced response to the
darunavir regimens. Two, I54M and T74P, are included in the
IAS-USA 2014 mutation list as a major and a minor darunavir
resistance mutation, respectively.16 Consistent with this, our
score gives the highest resistance weight to I54M and a some-
what lower weight to T74P. On the other hand, V11I but not
V11L, which we included in our score, is considered a minor resist-
ance mutation in that list. However, V11L and L10F are considered
accessory PI-resistance mutations that are associated with min-
imal reductions in darunavir susceptibility at the same level as
V11I.21 Finally, V82I is a highly polymorphic mutation that is not
selected by PIs and is the consensus amino acid in subtype G
viruses.21 We hypothesize that it may represent a marker or be
in linkage disequilibrium with other mutational haplotypes, either
within or outside the viral protease, translating into reduced in vivo
susceptibility to darunavir. Six additional protease mutations cor-
related with improved response to darunavir and received nega-
tive weights in the derived score. With the exception of V82A,
which has already been associated with improved response to
darunavir,19,36 no other of these mutations has been associated
with decreased or increased susceptibility to darunavir. Three,
E34D, I64L and I93L, are considered natural polymorphisms,
K20T is associated with variable resistance to other PIs, and
I85V is selected by PIs but has no impact on susceptibility to
Table 5. Comparative AUROC curves of different models using a binary outcome at week 8 (HIV-1 RNA reduction , or ≥1.5 log10 copies/mL)
Model AUROC Difference in AUROC Pa Difference in AUROC Pb
Subtype B (derivation set)
base model 0.804 reference
final model 0.844 0.040 ,0.001 reference
ANRS 2013 0.830 0.026 0.003 20.014 0.108
HIVdb 7.0 0.824 0.020 0.002 20.020 0.025
Rega 9.1.0 0.817 0.013 0.009 20.027 0.002
Subtype non-B (validation set)
base model 0.838 reference
final model 0.872 0.034 0.015 reference
ANRS 2013 0.840 0.002 0.390 20.032 0.016
HIVdb 7.0 0.840 0.001 0.690 20.032 0.015
Rega 9.1.0 0.853 0.015 0.140 20.019 0.190
All models include baseline CD4 and HIV-1 RNA and GSS of the accompanying drugs. The base model includes only baseline CD4 and HIV-1 RNA and GSS
of the accompanying drugs. The final model includes the weighted mutations as listed in Table 3 and the other models include a dummy variable
indicating susceptibility or resistance according to the three existing interpretation systems (see the Methods section).
aComparison with the base model.
bComparison with the final model.
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any of them.21 It should be underscored that the developed pre-
diction model includes baseline viral load, CD4 counts and GSS of
the antiretroviral drugs co-prescribed with darunavir and that
each contributes to improvement of prediction, as previously
shown by others,36 but it is noteworthy that inclusion of the dar-
unavir mutational score improved the prediction over the simple
use of these background features.
The findings of this paper are subject to several limitations.
First, we were not able to develop a subtype-specific tool predict-
ing virological response to darunavir. Indeed, although this study
included the largest standardized darunavir TCE set ever analysed,
the number of cases with individual non-B subtypes was limited
and did not allow specific predictions. In order to overcome this
limitation, future studies will need to address the role of specific
protease mutations in the context of the most common non-B
subtypes, such as C, A and D, and recombinants AE and AG, either
in vitro using site-directed mutagenesis experiments or in vivo
using well-defined TCEs from large cohorts in specific African or
Asian settings, as darunavir becomes more widely employed as
rescue therapy in these countries. Second, some of the estab-
lished darunavir resistance mutations did not appear in the
derived score. As a possible explanation, we hypothesize that
since patients from this study were selected from clinical practice,
most were prescribed darunavir based on results of a genotypic
resistance test, as indicated by the manufacturer, and thus daru-
navir was included in the salvage treatment mostly in the absence
of known darunavir resistance mutations. Since a selection bias
against these mutations has been applied in this dataset, their
absence in this newly derived score should be interpreted with
caution. Indeed, a prudent approach would be not to ignore
mutations that were shown to be predictive of reduced response
based on previous clinical trial analyses16,17,19,35 and to use the
newly derived score as an additional, refined darunavir genotypic
resistance interpretation tool. Moreover, rare mutations, which
may play a relevant role in predicting the virological outcome,
may have been missed due to their low prevalence in this study
dataset. Finally, this study allowed us to only predict the short-
term virological outcome, which may differ from longer-term
outcomes. However, short-term resistance genotype-guided
virological responses are significantly associated with long-term
virological outcomes.37 Moreover, short-term responses are
more strongly influenced by the antiviral activity of the regimen
and by its relationship with baseline resistance mutations, and
less by other confounders such as medication adherence and
toxicity, which are more influential on the longer-term.
The strong points of this study are the large number of daruna-
vir TCEs utilized, the uniform standardization of the data used
to define eligible TCEs and the significant proportion of non-B sub-
types analysed.
In conclusion, using a large, standardized dataset of geno-
type–response cases including darunavir-based regimens, we
derived and validated a new weighted score that outperformed
state-of-the-art darunavir GIS in predicting virological response
both in B and non-B subtypes. This score may be used for predict-
ing response to darunavir in individuals failing previous PIs with
different subtypes and thus be of help in designing the most
appropriate salvage regimens. However, mutations found in pre-
vious large clinical trials to be predictive of reduced virological
response and not included in this score should also be considered
in treatment decisions. After predicting treatment outcome of a
darunavir-based regimen using the new score, a prudent solution
for a user could be to check for the presence of additional major
darunavir resistance mutations on the IAS-USA list.16
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